

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/G88DB64E12E7EN.html>

Date: April 2020

Pages: 53

Price: US\$ 3,500.00 (Single User License)

ID: G88DB64E12E7EN

Abstracts

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020

SUMMARY

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020, outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Gamma-aminobutyric acid receptor subunit gamma-2 is a protein encoded by the GABRG2 gene. It functions also as histamine receptor and mediates cellular responses to histamine. It functions as receptor for diazepines and various anesthetics and as ligand-gated chloride channel.

The molecules developed by companies in Pre-Registration, Phase III and Preclinical stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Metabolic Disorders which include indications Sedation, General Anesthetic Effect, Hypercholesterolemia, Status Epilepticus and Substance (Drug) Abuse.

Furthermore, this report also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)

The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Overview

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Companies Involved in Therapeutics Development

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Co Ltd

Paion AG

Takeda Pharmaceutical Co Ltd

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Drug Profiles

clonazepam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EL-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HR-7056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LASSBio-785 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midazolam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Dormant Products

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Discontinued Products

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Product Development Milestones

Featured News & Press Releases

Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO

Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan

Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea

Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency

Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement

Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia

Jun 10, 2019: FDA accepts filing of NDA for Remimazolam

Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA

Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial

Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea

Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia

May 17, 2018: Paion announces clinical development progress with Remimazolam by

its partner R-Pharm in Russia

Jan 15, 2018: European Medicines Agency: Defect with Buccolam oral syringes

Nov 23, 2017: PAION Announces Clinical Development Progress with Remimazolam by its Partner Hana Pharma in South Korea

Nov 14, 2017: FDA Considers Current Human Abuse Liability Program with Remimazolam in the U.S. As Sufficient; no Second Intranasal Study Required

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Pipeline by Jiangsu Nhwa Pharmaceutical Co Ltd, H1 2020

Pipeline by Paion AG, H1 2020

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Co Ltd

Paion AG

Takeda Pharmaceutical Co Ltd

I would like to order

Product name: Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/G88DB64E12E7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G88DB64E12E7EN.html>